placeholder
Importance
52
Trust
89
Urgency
30
REGULATORY · PRIMARY SOURCE
FITISH - 728280 - 06/08/2026
The FDA warned Fitish, a compounding pharmacy, that it broke federal law by selling homemade versions of semaglutide and tirzepatide (weight-loss drugs) with false claims on its website. The company falsely suggested it made the drugs itself and implied they were FDA-approved, which is illegal for pharmacy-made copies.
Analysis
FDA keeps cracking down on compounders selling fake-branded semaglutide and tirzepatide copies. Less compounding supply pushes patients toward Novo's and Lilly's brand-name drugs.
- FDA issued warning letter MARCS-CMS 728280 to Fitish, Fort Worth TX, dated June 8, 2026
- Fitish website offered compounded semaglutide and tirzepatide with FITISH label, despite not being the compounder
- FDA review was conducted in March 2026; Fitish has 15 business days to respond
FDA Drug Approvals & Databases4d
Read